WilmerHale represented the joint-book running managers in the public offering of 5,880,000 shares of common stock of Xeris Pharmaceuticals, Inc. at a price to the public of $10.00 per share, for total gross proceeds to the Company of approximately $58.8 million (before underwriting discounts and expenses). In addition, Xeris has granted the underwriters an option for a period of 30 days to purchase up to an additional 882,000 shares of common stock at the public offering price, less the underwriting discount. The transaction priced on February 13, 2019 and closed on February 19, 2019.

The WilmerHale team on this deal included Lisa Firenze, Bruce Manheim, Colleen Superko, Ryan Mitteness, Howell Ma and Heidi Treiber.